Long-Term Exposure to Denosumab Does Not Exacerbate CKD
Researchers assessed the long-term safety and efficacy of denosumab in patients with mild to moderate chronic kidney disease (stages 2 and 3).
Researchers assessed the long-term safety and efficacy of denosumab in patients with mild to moderate chronic kidney disease (stages 2 and 3).
Clinical outcomes of and treatment for Kawasaki disease were found to be distinct for Black and White children.
Gout was not found to be associated with increased risk for cardiovascular complications in patients with peripheral artery disease.
The use of sodium-glucose transporter-2 inhibitors combined with metformin did not affect fracture risk in T2D.